Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.060
-1.880-3.92%
Volume:4.82M
Turnover:222.96M
Market Cap:305.70B
PE:33.46
High:47.940
Open:47.940
Low:45.740
Close:47.940
52wk High:94.869
52wk Low:45.660
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.51
T/O Rate:1.87%
Dividend:0.23
Dividend Rate:0.51%
EPS(LYR):1.376
ROE:12.46%
ROA:7.02%
PB:4.07
PE(LYR):33.46
PS:8.37

Loading ...

Hong Kong Stocks in Focus: METIS TECHBIO-P (07666) Surges Over 16% in Morning Trade as In-House AiTEM Platform Integrates with Jiangsu Hengrui Pharmaceuticals

Stock News
·
Aug 10

Hengrui Pharma Prioritizes Stable Business Performance to Sustain Long-Term Value and Reward Shareholders

Deep News
·
Aug 07

HENGRUI PHARMA Continues to Reward Shareholders Through Dividends and Other Methods

Deep News
·
Aug 07

Jiangsu Hengrui Pharmaceuticals Focuses on Core Business Growth

Deep News
·
Aug 07

Citigroup's Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 1.39% on Aug 3 from 2.36% - HKEX

THOMSON REUTERS
·
Aug 07

August 7th A-H Share Premium Data Summary

Stock News
·
Aug 07

HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval

Stock News
·
Aug 07

Movement Alert|HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications

Market Focus
·
Aug 07

Hengrui Pharma Unit Gets Marketing Nod for Colorectal Cancer Drug in China

MT Newswires Live
·
Aug 06

Hengrui Pharma Secures China’s First Anti-HER2 Approval for Colorectal Cancer with Trastuzumab Rezetecan

Bulletin Express
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approved Additional (Fifth) Indication for Ivarmacitinib Sulfate Tablets (Shr0302 Tablets)

THOMSON REUTERS
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approves Third Indication for Trastuzumab Rezetecan for Injection for Marketing in China

THOMSON REUTERS
·
Aug 06

JAK1 Inhibitor Aisuda Secures Fifth Indication Approval for Active Non-Radiographic Axial Spondyloarthritis

Deep News
·
Aug 06

Jiangsu Hengrui Pharmaceuticals Secures Approval for Third Indication of Its Anti-HER2 Injection

Stock News
·
Aug 06

Citigroup’s Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.06% on July 31 from 4.46% - HKEX Filing

THOMSON REUTERS
·
Aug 06

HENGRUI PHARMA's Zhang Lianshan: Global Strategy at a Turning Point, Innovative Drug Firms Must Ultimately Go Global Independently

Deep News
·
Aug 06

Movement Alert|HENGRUI PHARMA Falls 3.09% in Regular Trading, Trading at HK$56.35

Market Focus
·
Aug 06

Cross-Market Valuation Disparities: Top A-H Share Premium Rankings as of August 5th

Stock News
·
Aug 05

Hengrui Pharmaceuticals Gets China Nod for Lung Cancer Combo Trials

MT Newswires Live
·
Aug 05

Hengrui Pharma Completes 13.75 Million Share Buyback as of July 31

Stock News
·
Aug 04